What's Happening?
Phanes Therapeutics, a clinical stage biotech company based in San Diego, has announced the initiation of the dose expansion phase in their clinical study of spevatamig, a bispecific antibody, in combination
with chemotherapy for the treatment of biliary tract cancer (BTC). This follows the clearance of dose-limiting toxicity at two dose levels. Spevatamig targets claudin 18.2 and CD47 and has been granted orphan drug designation for pancreatic cancer and Fast Track designation for metastatic claudin 18.2-positive pancreatic adenocarcinoma by the FDA. The company is conducting multiple Phase 2 trials with spevatamig, including studies on pancreatic ductal adenocarcinoma. Over 160 patients globally have been treated with spevatamig in various settings. Phanes is also collaborating with Merck to study spevatamig in combination with pembrolizumab, an anti-PD-1 therapy.
Why It's Important?
The expansion of the clinical study for spevatamig is significant as it represents a potential advancement in the treatment of biliary tract cancer, a condition with limited therapeutic options. The orphan drug and Fast Track designations by the FDA highlight the unmet medical need and the potential of spevatamig to address it. This development could lead to improved outcomes for patients with BTC and other cancers expressing claudin 18.2. The collaboration with Merck further underscores the potential of spevatamig in combination therapies, which could enhance its efficacy and broaden its application in oncology.
What's Next?
Phanes Therapeutics will continue to monitor the outcomes of the dose expansion phase and gather data on the efficacy and safety of spevatamig in combination with chemotherapy. The results of these studies will be crucial in determining the next steps, including potential regulatory submissions and further clinical trials. The upcoming presentation of clinical posters at the American Association for Cancer Research Annual Meeting 2026 will provide additional insights into the progress and findings of the ongoing studies.
